Associations - MAP2K1 mutation

MAP2K1 mutation MAP2K1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MAP2K1 mutation MAP2K1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	avelumab + binimetinib Sensitive: C3 – Early Trials SITC 2021 - 2 weeks	avelumab + binimetinib Sensitive: C3 – Early Trials SITC 2021 - 2 weeks
MAP2K1 mutation MAP2K1 mutation	Non Small Cell Lung Cancer NSCLC	MAP2K1 mutation MAP2K1 mutation	Non Small Cell Lung Cancer NSCLC	lorlatinib Resistant: C3 – Early Trials	lorlatinib Resistant: C3 – Early Trials
MAP2K1 mutation MAP2K1 mutation	Melanoma Melanoma	MAP2K1 mutation MAP2K1 mutation	Melanoma Melanoma	CTLA4 inhibitor Sensitive: C3 – Early Trials	CTLA4 inhibitor Sensitive: C3 – Early Trials
MAP2K1 mutation MAP2K1 mutation	Biliary Tract Cancer Biliary Tract Cancer	MAP2K1 mutation MAP2K1 mutation	Biliary Tract Cancer Biliary Tract Cancer	trametinib Sensitive: C3 – Early Trials	trametinib Sensitive: C3 – Early Trials
MAP2K1 mutation MAP2K1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	MAP2K1 mutation MAP2K1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	binimetinib Sensitive: C3 – Early Trials	binimetinib Sensitive: C3 – Early Trials
MAP2K1 mutation MAP2K1 mutation	Ovarian Cancer Ovarian Cancer	MAP2K1 mutation MAP2K1 mutation	Ovarian Cancer Ovarian Cancer	selumetinib Sensitive: C4 – Case Studies	selumetinib Sensitive: C4 – Case Studies
MAP2K1 mutation MAP2K1 mutation	Melanoma Melanoma	MAP2K1 mutation MAP2K1 mutation	Melanoma Melanoma	dabrafenib Resistant: D – Preclinical	dabrafenib Resistant: D – Preclinical
MAP2K1 mutation MAP2K1 mutation	Melanoma Melanoma	MAP2K1 mutation MAP2K1 mutation	Melanoma Melanoma	trametinib Resistant: D – Preclinical	trametinib Resistant: D – Preclinical